Melanocortin / sexual-effect comparison
Bremelanotide vs Melanotan II
Bremelanotide has Phase III indication-specific evidence; Melanotan II has only very small early human development and substantially weaker safety evidence.
At a glance
Bremelanotide
Melanotan II
Human evidence
Two Phase III RECONNECT trials support bremelanotide for acquired generalized HSDD in premenopausal women. Older intranasal studies also reported male ED signals, but that is not the approved indication.
Very small human studies demonstrate pigmentation and erectogenic/sexual-desire effects, including placebo-controlled ED studies, but these do not establish routine therapeutic or cosmetic use.
Research focus
Hypoactive sexual desire disorder (HSDD)
Pigmentation and sexual-function research
Regulatory status
U.S. Vyleesi is approved for acquired generalized HSDD in premenopausal women; it is not indicated for men or to enhance sexual performance.
Not FDA-approved as a tanning medicine; FDA lists significant safety concerns for compounded Melanotan II.
Route / formulation
Research-market PT-141 is not automatically equivalent to the authorised Vyleesi product.
Small research trials do not establish safety of internet-sourced tanning products.
No modern head-to-head clinical trial Bremelanotide has Phase III indication-specific evidence; Melanotan II has only very small early human development and substantially weaker safety evidence.